Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.
Experience finance made simple on the new ABCD app!
Scan to Download the App
One stop solution for all stock market enthusiasts
Whatsapp us!! We are Available.
Send HI on 8828800038
For Broking services
Call Toll Free Number :
1800-270-7000
( Mon - Fri: 9AM - 11PM )
( Sat & Sun: 9AM - 09PM )
Call N Trade
Call :
1800-108-9999
( 9AM to 11:30PM /11:55PM )
Acquire & service self-trading online & offline clients. Archive large-scale business success with the entire product range offered by us.
Earn while you refer client. No need to set up your own infrastructure.
Join our referral program, earn rewards when friends and family open accounts & transact. Spread the word, multiply your earnings!
Join the Entrepreneurial Tribe!
Aditya Birla Money Limited
NIFTY 22,713.10 (0.15%)
Sensex 73,319.55 (0.25%)
GOLD 149,610.00 (-2.67%)
USDINR 93.02 (-0.16%)
UPDATED ON : (04 Mar 2026)
The cost of subscription stands at 1,000,000 Chilean pesos towards share capital contribution, comprising 1,000,000 shares. The entire share capital of Tripharma Chile SpA will be held by Pinnacle Chile SpA, making it a wholly owned step-down subsidiary of the company.
Aarti Drugs was established in the year 1984 and forms part of the $6 billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates and speciality chemicals and produces formulations with its wholly-owned subsidiary, Pinnacle Life Science.
The company reported a 9.4% increase in consolidated net profit to Rs 40.54 crore on an 8.1% rise in net sales to Rs 601.71 crore in Q3 FY26 as compared with Q3 FY25.